Abstract

References 34

[1]	Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol, 2014, 61: S45-S57.
[2]	Huang YW, Yang SS, Fu SC, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: A nationwide cohort study. Hepatology, 2014, 60: 807-814.
[3]	中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2015更新版).中华肝脏病杂志,2015,23:906-923.
[4]	Ge D, Fellay J, Thompson A J, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 2009, 461: 399-401.
[5]	Liao XW, Ling Y, Li XH, et al. Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir Ther, 2011, 16: 141.
[6]	Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet, 2009, 41: 1100-1104.
[7]	Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet, 2009, 41: 1105-1109.
[8]	McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. New Engl J Med, 2009, 361: 580-593.
[9]	Aka PV, Kuniholm MH, Pfeiffer RM, et al. Association of the IFNL4-ΔG allele with impaired spontaneous clearance of hepatitis C virus. J Infect Dis, 2014, 209: 350-354.
[10]	Wu R, Chi X, Wang X, et al. IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection. Infect Genet Evol, 2016, 39: 132-140.
[11]	Franco S, Aparicio E, Parera M, et al. IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients. AIDS, 2014, 28: 133-136.
[12]	Covolo L, Bibert S, Donato F, et al. The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. Aliment Pharm Thera, 2014, 39: 322-330.
[13]	Dai CY, Chuang WL, Hsieh MY, et al. Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients. Antivir Res, 2010, 85: 396-402.
[14]	Fitzmaurice K, Hurst J, Dring M, et al. Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. Gut, 2015, 64:813-819.
[15]	Yee LJ, Im KA, Wahed AS, et al. Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C. Antimicrob Agents Ch, 2009, 53: 615-621.
[16]	Wang J, Feng Z, Li Y, et al. Association of tumor necrosis factor-α gene promoter polymorphism at sites-308 and-238 with non-alcoholic fatty liver disease: A meta-analysis. J Gastroen Hepatol, 2012, 27: 670-676.
[17]	Dai CY, Chuang WL, Chang WY, et al. Tumor Necrosis Factor-α Promoter Polymorphism at Position-308 Predicts Response to Combination Therapy in Hepatitis C Virus Infection. J Infect Dis, 2006, 193: 98-101.
[18]	Grandi T, Silva CM, Amaral KM, et al. Tumour necrosis factor-308 and-238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients. Mem Inst Oswaldo Cruz, 2014, 109: 345-351.
[19]	Carneiro VL, Lemaire DC, Bendicho MT, et al. Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders. Liver Int, 2010, 30: 567-573.
[20]	Vidal-Castieira JR, López-Vázquez A, Diaz-Pena R, et al. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. Journal of virology, 2010, 84: 475-481.
[21]	Knapp S, Warshow U, Hegazy D, et al. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology, 2010, 51: 1168-1175.
[22]	Hu X, Jiang Y, Li X, et al. Long-Term Effect on Natural Killer Cells by Interferon-α Therapy on the Outcomes of HCV Infection. J Interferon Cytokine Res, 2014, 34: 366-375.
[23]	Umemura T, Ota M, Katsuyama Y, et al. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C. Hum Immunol, 2014, 75: 822-826.
[24]	Suzuki F, Arase Y, Suzuki Y, et al. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat, 2004, 11: 271-276.
[25]	Hijikata M, Mishiro S, Miyamoto C, et al. Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (-123 and-88) in vivo and in vitro. Intervirology, 2002, 44: 379-382.
[26]	Chen H, Zhang Y, Huang P, et al. Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients. J Biomed Res, 2014, 28: 476.
[27]	Nattermann J, Vogel M, Nischalke HD, et al. The transforming growth factor-β high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C. AIDS, 2008, 22: 1287-1292.
[28]	Saxena A, Khosraviani S, Noel S, et al. Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine, 2015, 74: 27-34.
[29]	Afzal MS, Anjum S, Zaidi NU. Effect of functional interleukin-10 polymorphism on pegylated interferon-α plus ribavirin therapy response in chronic hepatitis c virus patients infected with 3a genotype in Pakistani Population. Hepat Mon, 2013, 13.
[30]	Abdelraheem WM, Hassuna NA, Abuloyoun SM, et al. Interleukin-10. rs1800896 and Interleukin-18. rs1946518 gene polymorphisms could not predict the outcome of hepatitis C virus infection in Egyptian patients treated with pegylated interferon plus ribavirin. Arch Virol, 2016, 161: 2473-2480.
[31]	Matsue Y, Tsutsumi M, Hayashi N, et al. Serum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection. PloS one, 2015, 10: e0118744.
[32]	Imran M, Manzoor S, Parvaiz F. Predictive potential of IL-18? 607 and osteopontin? 442 polymorphism in interferon-based therapy of HCV infection in the Pakistani population. Viral Immunol, 2014, 27: 404-411.
[33]	Naito M, Matsui A, Inao M, et al. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol, 2005, 40: 381-388.
[34]	Shaker O, El-Shehaby A, Fayez S, et al. Osteopontin gene polymorphisms as predictors for the efficacy of interferon therapy in chronic hepatitis C Egyptian patients with genotype 4. Cell Biochem Funct, 2013, 31: 620-625.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 34

Related Articles 0

Recommended Articles 0

Metrics

Comments